相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil
Lei Xi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2023)
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
Alice Dragomir et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study
Chris H. M. Wong et al.
PROSTATE (2023)
Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease
Shivanshu Awasthi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
Mohammad Abufaraj et al.
EUROPEAN UROLOGY (2021)
Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist
David Margel et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice
Patrick Davey et al.
WORLD JOURNAL OF UROLOGY (2021)
Cardiovascular Toxicities of Androgen Deprivation Therapy
Azariyas A. Challa et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
Daniel J. George et al.
FUTURE ONCOLOGY (2021)
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study
Dong-Yi Chen et al.
PROSTATE (2021)
Cardiovascular Toxicity of Androgen Deprivation Therapy
Julia Boland et al.
CURRENT CARDIOLOGY REPORTS (2021)
Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
Alessandro Sciarra et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
Fred Saad et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities
Grace Lu-Yao et al.
EUROPEAN UROLOGY (2020)
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses
Jiun-Ruey Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Cardiovascular risk with androgen deprivation therapy
Matt T. Rosenberg
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2020)
Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis
Valentina Perrone et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
E. David Crawford et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer
Celestia S. Higano
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017
David A. Siegel et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer
Martina Maggi et al.
JOURNAL OF UROLOGY (2020)
Cardiovascular Complications of Prostate Cancer Therapy
Courtney M. Campbell et al.
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE (2020)
Cardiovascular Complications of Prostate Cancer Therapy
Courtney M. Campbell et al.
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE (2020)
Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease
David Margel et al.
JOURNAL OF UROLOGY (2019)
Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis
Jiatong Zhou et al.
BMC CANCER (2019)
Midlife metabolic factors and prostate cancer risk in later life
Barbra A. Dickerman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Roberto Iacovelli et al.
CLINICAL GENITOURINARY CANCER (2018)
Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals
Valerie D. Myers et al.
JAMA CARDIOLOGY (2018)
Cardiovascular Diseases in African Americans: Fostering Community Partnersnips to Stem the Tide
George A. Mensah
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology
Robert Steven Gerhard et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
Raphael B. Moreira et al.
ONCOTARGET (2017)
African-American Prostate Cancer Disparities
Zachary L. Smith et al.
CURRENT UROLOGY REPORTS (2017)
Body size across the life course and prostate cancer in the Health Professionals Follow-up Study
Elisabeth Moller et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Cardiovascular risk patients under androgen deprivation therapy. Lower risk with GnRH antagonists compared to LHRH agonists?
Axel S. Merseburger et al.
UROLOGE (2016)
Cardiovascular risk patients under androgen deprivation therapy. Lower risk with GnRH antagonists compared to LHRH agonists?
Axel S. Merseburger et al.
UROLOGE (2016)
Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review
Fanzheng Meng et al.
BMC CANCER (2016)
Ethnic Minorities and Coronary Heart Disease: an Update and Future Directions
J. Adam Leigh et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer
Ada S. Cheung et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Metabolic syndrome in prostate cancer: impact on risk and outcomes
Fatima H. Karzai et al.
FUTURE ONCOLOGY (2016)
Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
Jeremy Yuen Chun Teoh et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2016)
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice
Anki Knutsson et al.
SCIENTIFIC REPORTS (2016)
Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice
Christian Bo Poulsen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer
Roberto Iacovelli et al.
EUROPEAN JOURNAL OF CANCER (2015)
The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona
Cristiane Murta-Nascimento et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2015)
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Cecilia Bosco et al.
EUROPEAN UROLOGY (2015)
Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
Sean O'Farrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis
Arie Carneiro et al.
WORLD JOURNAL OF UROLOGY (2015)
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study
Giorgio Gandaglia et al.
BJU INTERNATIONAL (2014)
Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race
Leonard C. Edelstein et al.
BLOOD (2014)
Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database
Emma H. Allott et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study
Christina G. Jespersen et al.
EUROPEAN UROLOGY (2014)
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Peter C. Albertsen et al.
EUROPEAN UROLOGY (2014)
Daily Aspirin Use and Prostate Cancer-Specific Mortality in a Large Cohort of Men with Nonmetastatic Prostate Cancer
Eric J. Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies
Jinsheng Zhao et al.
PLOS ONE (2014)
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
L. Bourke et al.
BRITISH JOURNAL OF CANCER (2013)
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial
Daniel A. Barocas et al.
CANCER (2013)
Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men
Isaac J. Powell et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Does Comorbidity Influence the Risk of Myocardial Infarction or Diabetes During Androgen-Deprivation Therapy for Prostate Cancer?
Nancy L. Keating et al.
EUROPEAN UROLOGY (2013)
Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c
Leonard C. Edelstein et al.
NATURE MEDICINE (2013)
Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men
Matthias Moehlig et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials
Paul L. Nguyen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Community Prevalence of Ideal Cardiovascular Health, by the American Heart Association Definition, and Relationship With Cardiovascular Disease Incidence
Aaron R. Folsom et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Race, healthcare access and physician trust among prostate cancer patients
Young Kyung Do et al.
CANCER CAUSES & CONTROL (2010)
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Nancy L. Keating et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
Jason A. Efstathiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer
Christopher J. DiBlasio et al.
BJU INTERNATIONAL (2008)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Tobias Pischon et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Christopher S. Saigal et al.
CANCER (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin sensitivity during combined androgen blockade for prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
